Skip to main content

Table 3 AEs in patients with EGFR Mut + NSCLC treated with gefitinib (≥ 2% of patients)

From: Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

  n
(N = 222)
%
All 129 58.1
Dermatology/skin
 Rash: acne/acneiform 53 23.9
 Dry skin 24 10.8
 Nail changes 14 6.3
 Pruritus/itching 14 6.3
 Dermatology/skin – other 11 5.0
 Hair loss/alopecia 9 4.1
 Rash/desquamation 8 3.6
Gastrointestinal
 Diarrhea 40 18.0
 Nausea 17 7.7
 Vomiting 8 3.6
Cardiac general
 Cardiac ischemia/infarction 5 2.3
Constitutional symptoms
 Constitutional symptoms – other 6 2.7
 Fatigue (asthenia, lethargy, malaise) 5 2.3
Ocular/visual
 Other 6 2.7
Hemorrhage/bleeding
 Hemorrhage, pulmonary/upper respiratory – nose 5 2.3
Neurology
 Neuropathy: sensory 5 2.3
Pulmonary/upper respiratory
 Dyspnea (shortness of breath) 5 2.3
Renal/genitourinary
 Cystitisa 4 1.8
  1. Adverse events by CTC symptoms related to gefitinib and serious adverse events related and not related to gefitinib. AE, adverse event; CTC, Common Toxicity Criteria; NSCLC, non-small-cell lung cancer. aIncludes one patient in whom cystitis was not related to gefitinib and was not serious
\